scholarly journals Diagnostic utility of serum melatonin levels in systemic lupus erythematosus: a case-control study

Reumatismo ◽  
2017 ◽  
Vol 69 (4) ◽  
pp. 170 ◽  
Author(s):  
A.B. Rasheed ◽  
M.S. Daoud ◽  
F.I. Gorial

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune inflammatory disease and early diagnosis is of clinical and therapeutic importance. Melatonin is an endogenous endolamine hormone that plays an important role in the immune system due to its anti-inflammatory action. This study was designed to assess serum melatonin levels in SLE patients and to evaluate the possible correlation between serum melatonin and patients’ baseline characteristics. A case-control study was performed on 50 SLE patients (48 females and 2 males), diagnosed according to the revised 1997 ACR Criteria, and 25 healthy controls (24 females and 1 male), matched by age and sex. Daily serum melatonin levels were investigated in all participants using human melatonin enzyme linked immunosorbent assay (ELISA) kit (MYBIOSOURCE (MBS), United States). Serum melatonin concentration was significantly lower in patients with SLE compared to healthy controls (19.17±6.86 pg/mL vs 23.26±6.71 pg/mL, p=0.017). Serum melatonin concentration ≤18.51 pg/mL was the optimum cut off value to differentiate between SLE patients and healthy controls with an accuracy of 69.3%, a sensitivity of 66%, and a specificity of 76%. The positive predictive value (PPV) at pretest 50% was 73.3% and PPV at pretest 90% was 96.1%; the negative predictive value (NPV) at 10% was 95.3%. Patients’ characteristics were not significantly correlated with serum melatonin concentrations using multiple logistic regression analysis. Serum melatonin was a valid measure to differentiate between SLE patients and healthy controls with good accuracy, sensitivity and specificity and PPV and NPV. There was no significant correlation between serum melatonin concentrations and patients’ baseline characteristics.

Reumatismo ◽  
2020 ◽  
Vol 72 (3) ◽  
pp. 145-153
Author(s):  
A. Fayed ◽  
M.M. El Menyawi ◽  
M. Ghanema ◽  
O. Shaker ◽  
R. Elgohary

Much evidence highlighted the role of interferon alpha (IFN-α) in systemic lupus erythematosus (SLE) and suggested its possible role in assessing disease activity. We measured serum IFN-α in Egyptian SLE patients in order to determine a cutoff value that can be used to distinguish patients from healthy controls and explored its clinical value in monitoring disease activity and different aspects of the disease, in particular lupus nephritis. This cross-sectional, case-control study was conducted on 59 SLE patients and 30 healthy controls. Serum IFN-α was measured in all participants using sensitive enzyme-linked immunosorbent assay (ELISA). SLE patients underwent assessment of disease activity using the SLE disease activity index-2000 (SLEDAI-2K) as well as an evaluation of proteinuria, complement C3 and C4, and serology. Patients with evidence of renal involvement underwent renal biopsy. The median serum IFN-α was 81.8 pg/mL (interquartile range [IQR] 63.4:102.4), which was significantly higher than in healthy controls (median 10.3 pg/mL [IQR 7.3:11.6]) (p<0.001). At serum level of 14.7 pg/mL, IFN-α has high sensitivity and specificity to discriminate SLE patients from controls, with high positive and negative predictive values. Serum IFN-α was not associated with markers of disease activity, clinical features and anti-double stranded DNA. Furthermore, it was not associated with markers of renal activity, including proteinuria, C3 and C4 complement factors and histopathology renal classes. Despite elevated levels of serum IFN-α in SLE patients, it is not possible to use it as a biomarker for disease activity.


2016 ◽  
Vol 181 (10) ◽  
pp. 1348-1356 ◽  
Author(s):  
Barbara H. Bardenheier ◽  
Jonathan Duffy ◽  
Susan K. Duderstadt ◽  
Jay B. Higgs ◽  
Michael P. Keith ◽  
...  

2018 ◽  
Vol 29 (7) ◽  
pp. 732-739 ◽  
Author(s):  
Chien-Hung Lin ◽  
Peir-Haur Hung ◽  
Hsiao-Yun Hu ◽  
Chi-Jung Chung ◽  
Tsung-Hsien Chen ◽  
...  

Author(s):  
Brena Rodrigues Manzano ◽  
Paulo Sérgio da Silva Santos ◽  
Matheus Henrique Bariquelo ◽  
Nathália Rodrigues Germano Merlini ◽  
Heitor Marques Honório ◽  
...  

Lupus ◽  
1999 ◽  
Vol 8 (2) ◽  
pp. 151-157 ◽  
Author(s):  
A Fernández-Nebro ◽  
R Palacios-Muñoz ◽  
J Gordillo ◽  
M Abarca-Costalago ◽  
M De Haro-Liger ◽  
...  

2020 ◽  
Vol 10 (01) ◽  
pp. e12-e15
Author(s):  
Banafsheh Sadeghi ◽  
Elham Rayzan ◽  
Fatemeh Tahghighi ◽  
Mamak Shariat ◽  
Fatemeh Nayeri ◽  
...  

AbstractBreast milk is a rich source of infants' nutrition and also known to be a source of immune-enhancing molecules. The perinatal factors might have long-term effects on the immune system and also, breastfeeding may have an important role. Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease that leads to various organ damages. This idiopathic disease is characterized by high levels of autoantibodies in the circulation. In this case–control study, we have evaluated the association between the breastfeeding and mode of delivery and SLE incidence. In this case–control study, SLE cases were identified in Children's Medical Center and Imam Khomeini Hospital Complex between 2011 and 2017. The control group was chosen from the schools of Tehran and Sari cities. The questionnaires were completed by one of the parents. Seventy-nine cases and 301 controls were included. There was no association among breastfeeding, duration of breastfeeding or exclusive breastfeeding and SLE, the age of diagnosis, or its major organ involvements (p > 0.05). The cesarean section (C-section) method was significantly associated with higher disease incidence (p < 0.005). The feeding method during infancy had no significant impact on SLE incidence and onset, while the C-section method increased the incident rate.


Sign in / Sign up

Export Citation Format

Share Document